McKesson Ventures, Novartis Venture Fund and Merck Global Health Innovation Fund took part in a round for biomarker developer Koneska.
Koneksa, a US-based developer of digital biomarkers for drug development, has raised $16m in its series B round from a consortium including multiple healthcare companies’ corporate venturing units.
McKesson Ventures, Novartis Venture Fund and Merck Global Health Innovation Fund, representing their pharma parents, invested in the B round, which was led by investment firms Spring Mountain Capital, and which also featured MBX Capital and Waterline Ventures.
Founded in 2015, Koneksa started with incubation support from Merck Global Health Innovation Fund and…
